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Vanadium is a trace element mainly connected with regulation of insulin metabolism which is particularly important in diabetes. In 
recent years, organic complexes of vanadium seem to be more interesting than inorganic salts. Nevertheless, the effect of vanadium 
on lipid metabolism is still a problematic issue; therefore, the main purpose of this study was to investigate the effect of 3 organic 
complexes ofvanadium such as sodium (2,2,-bipyridine)oxidobisperoxovanadate(V) octahydrate, bis(2,2,-bipyridine)oxidovana- 
dium(IV) sulfate dehydrate, and bis(4,4,-dimethyl-2,2,-bipyridine)oxidovanadium(IV) sulfate dihydrate in conjunction with high- 
fat as well as control diet in nondiabetes model on the following lipid parameters: total cholesterol, triglycerides, and high density 
lipoprotein as well as activity of paraoxonase 1. All of these parameters were determined in plasma of Wistar rats. The most 
significant effect was observed in case of bis(4,4ł-dimethyl-2,2ł bipyridine)oxidovanadium(IV) sulfate dehydrate in rats fed with 
high-fat diet. Based on our research, bis(4,4,-dimethyl-2,2,-bipyridine)oxidovanadium(IV) sulfate dihydrate should be the aim of 
further research and perhaps it will be an important factor in the regulation of lipid metabolism.
1. Introduction
Vanadium is a trace element on which a lot of attention 
was paid in context of diabetes. Initially, vanadium com- 
pounds were supposed to be insulin mimetic; however, now 
this element is mainly considered as a mean of increasing 
sensitivity of hepatocytes and myocytes on the effect of this 
hormone. Regulation by vanadium among other activities of 
the protein tyrosine phosphatase-lB (PTP-1B) is particularly 
important [1]. Probably the excessive activity of protein tyro­
sine phosphatase can affect insulin resistance [2]. The effect of 
vanadium compounds on glucose transport involving protein 
GLUT-4 was indicated too [3, 4 ]. What is more, this element 
activates also enzymes involved in glycolysis and glycogenesis 
as well as lipid metabolism [5].
Nowadays, the effect of vanadium on carbohydrate 
metabolism is getting better known, while the effect on lipid 
metabolism is still a problematic issue. Study indicating dys- 
lipidemic properties of organic complexes of vanadium was 
conducted in diabetes model [6]; nevertheless, there is still 
lack of research evaluating these properties in nondiabetes 
model. Disturbance of lipid metabolism is a basic factor in 
development of cardiovascular diseases, which are currently 
one of the main reasons for mortality [7, 8]. Statins are 
common drugs used in treatment of such patients. However, 
there is an urgent need of search for alternative forms 
of treatment for patients with contraindications of statins. 
Therefore, the main purpose of this study was to investigate 
the effect of 3 organic vanadium complexes on selected lipid 
parameters in rats fed with a high-fat diet.
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Paraoxonase 1 (PON1) is an enzyme involved in lipid 
metabolism, for example, by limiting HDL and LDL oxi- 
dation. Moreover, this enzyme is also known for anti- 
inflammatory properties [9]. Meta-analyses indicated a cor- 
relation between risk of cardiovascular disease and PON1 
activity among people independent of age or ethnicity [10, 
11]. On the other hand, inadequate diet can contribute to 
reduction level of expression of that enzyme [12]. Taking into 
account a protective role of PON1 in cardiovascular diseases, 
we found it also necessary to evaluate the influence of these 
vanadium complexes on this parameter. Because this enzyme 
is calcium-dependent, we analyzed this element as well.
2. Materials and Methods
2.1. Reagents. The reagents were purchased from Sigma Aldrich 
Chemical Company (Steinheim, Germany) and Avantor Per­
formance Materials Poland S.A.
2.2. Synthesis ofVanadium  Complexes. In this study, the fol- 
lowing complexes were used: sodium  (2,2; -bipyridine)oxi- 
dobisperoxidovanadate(V) octahydrate, Na[VO (O 2)2(2,2;- 
bpy)]-8H2O, marked as V (453.9 g/mol); bis(2,2;-bipyri- 
dine)oxidovanadium(IV) sulfate dihydrate, [VO(SO4)(2,2;- 
bpy)]-2H 2O, m arked as B (511.21 g/m ol); and b is(4 ,4 ;- 
dimethyl-2,2/-bipyridine)oxidovanadium(IV) sulfate dihy­
drate, [VO(4,4/-Me-2,2/-bpy)2]SO4-2H2O marked as Bm 
(567.21 g/mol). Synthesis of the first compound V was described 
[13]. In turn, synthesis of compound B was described [14]. In 
case of Bm compound, process of synthesis was similar to B 
complex except molar ratio of ligand to vanadium which was 
2 : 1. The purity of all analyzed complexes was confirmed by 
microanalysis and IR spectroscopy.
2.3. Animals. In the experiment, male Wistar rats aged 
3 months and weighing 250 ± 15 g were divided into 
8 groups of 6 animals. During the time of experiment 
(5 weeks), each group of animals was fed with different 
diet: group CN, standard diet (starch—62%, casein—20%, 
oil—5.0%, calcium carbonate—2.8%, Ca3(PO4)2—2.9%, 
lecithin—1.0%, NaCl—0.3%, cellulose—4.7%, minerals and 
vitamins m ix.—1.0%, M gO—0.07%, and K 2SO4—0.23%); 
group CV, standard diet +  vanadium complex V; group 
CB, standard diet +  vanadium complex B; group CBm, 
standard diet +  vanadium complex Bm; group AN, high 
fatty diet (starch—32%, casein—20%, oil—5.0%, lard—30%, 
calcium carbonate—2.8%, C a3(PO4)2—2.9%, lecithin—1.0%, 
NaCl—0.3%, cellulose—4.7%, minerals and vitamins 
m ix.—1.0%, M gO—0.07%, and K 2SO4—0.23%); group AV, 
high fatty diet + vanadium complex V; group AB, high fatty 
diet + vanadium complex B; group ABm, high fatty diet 
+ vanadium complex Bm. In all vanadium treated groups, 
tested complexes were administered by gavage once a day 
during 5 weeks in the dose of 20 m g/kg body mass.
All animals had free access to feed and water and were 
kept in a room with a constant temperature of 23°C and 
50-60% humidity with a 12-hour day/night cycle. After 5 
weeks, the animals were anesthetized. This experience was 
conducted with an approval of I Local Ethics Committee for
Animal Experiments of Jagiellonian University in Cracow, 
number 80/2009 17.09.2009.
2.4. Blood Preparation. Blood samples were taken from aorta 
into heparinized tubes and then centrifuged (at 2500 xg  for 15 
minutes at 4°C) to obtain plasm a which was kept frozen (at 
-80°C ) until further analyses.
2.5. Biochemical Parameters. Biochemical analysis was done 
using standard biochemical analyzer Alize BioMerieux with 
standard kits (Ca—61041, TCHO L—61218, TG —61236, 
H DL—61001 and 61002) from BioMerieux. Thus, the 
obtained results were compared with Control Serum 1, 
ODC0003, and Control Serum 2, ODC0004 (OLYMPUS).
2.6. Paraoxonase 1 Activity (PON1) in Plasma. Paraoxonase
1 (PON1) activity was determined by modified Eckerson 
method [15]. A mixture of 0.25 M Tris buffer (pH 8) and 
0.1 M paraoxon in a volume ratio of 19: 1 (v/v) was added 
to samples. Then, the absorbance was measured at 412 nm 
during 2 minutes. PON1 activity was estimated based on 
changes in concentration of substrate.
2.7. Statistical Analysis. We used two-way analysis ofvariance 
(ANOVA) in order to verify if the examined factors (explana- 
tory variables) influence the observed (dependent) variables 
[16]. Before this, we had checked if the main assumptions 
concerning normal distribution of dependent variable within 
groups as well as homogeneity of variance were met [17]. 
Normal distribution was verified by Shapiro-Wilk test while 
homogeneity of variance was verified by Levene’s test. In turn, 
Box-Cox transformation was used for variables which did not 
meet ANOVA assumptions [17, 18].
Analysis of variance was conducted for each of the fol- 
lowing dependent variables: Ca [mmol/l], TCHOL [mmol/l], 
TG [mmol/l], HDL [mg/dL], and PON1 [U/mg protein]. 
Intragroup factors were the type of diet (X1-diet) and type 
of supplement (X2-supplement). Type of diet (X1-diet) had
2 levels (C and A); in turn, type of supplement (X2- 
supplement) had 4 levels (N, B, V, and Bm).
Tukey’s test was used to indicate homogeneous groups 
(marked by identical letters). All analyses were conducted at 
significance level p  =  0.05. Obtained data were statistically 
analyzed using the STATISTICA (StatSoft, Inc. (2011) version 
10, http://www.statsoft.com.).
Based on Levene’s test, 3 variables such as TCHOL 
[mmol/l], TG [mmol/l], and PON1 [U/mg protein] did not 
meet assumption of homogeneity of variance. Therefore, 
for them, Box-Cox transformation was made after which 
variables met the assumption concerning normal distribution 
(Shapiro-Wilk test) and homogeneity of variance (Levene’s 
test) at significance level p  =  0.05. Then, two-way analysis 
ofvariance (ANOVA) was used.
3. Results
The results are summarized in Table 1. All parameters were 
analyzed in plasm a of rats. Bm vanadium complex in control 
diet (CBm) statistically increased (p  < 0.05) concentration 
of calcium compared to control diet (CN). In case of V
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T ab le  1: Biochemical parameters. Data are presented as means from independent measurements ± standard deviation (SD).
X1-diet X2-supplement Name group Ca [mmol/l] TCHOL [mmol/l] TG [mmol/l] HDL [mg/dL] PON1 [U/mg protein]
C N CN 3.13 ±0 .27a 1.99 ± 0.48a 1.28 ±0.14bc 33.11 ±6.60ab 366 ± 98bc
C V CV 3.2 ±0.15ab 1.98 ± 0.36a 1.21 ± 0.09c 39.65 ± 6.58ab 207 ± 43a
C B CB 3.23 ±0.17ab 1.56 ± 0.41a 1.41 ± 0.30c 39.87 ± 8.40ab 362 ± 97bc
C Bm CBm 3.48 ± 0.33b 1.72 ± 0.36a 1.56 ± 0.44c 41.49 ± 7.40a 311 ± 52abc
A N AN 3.03 ±0 .11a 1.76 ± 0.04a 0.63 ±0 .13a 25.68 ±9.01b 386 ± 23c
A V AV 3.36 ± 0.19b 2.15 ± 0.30ab 1.13 ±0.12bc 35.34 ±2.60b 313 ± 56abc
A B AB 3.04 ± 0.21a 2.17 ± 0.53b 1.11 ±0.24bc 41.99 ± 8.00a 260 ± 54ab
A Bm ABm 2.97 ± 0.33a 2.80 ±0.36b 0.84 ± 0.17a 41.89 ±8.10a 202 ± 55a
CN: control diet without additives; CV: V vanadium compounds with control diet; CB: B vanadium compounds with control diet; CBm: Bm vanadium 
compounds with control diet; AN: high-fat diet without additives; AV: V vanadium compounds with high-fat diet; AB: B vanadium compounds with high-fat 
diet; ABm: Bm vanadium compounds with high-fat diet.
Ca: calcium; TCHOL: total cholesterol; TG: triglycerides; HDL: high-density lipoprotein, PON1: activity of paraoxonase 1.
Means in the same columns followed by different letters (a, b, c) are significantly different at p < 0.05 according to Tukeys test.
vanadium complex in control diet (CV), activity of PON 1 
significantly decreased (p  < 0.05) compared to control diet 
(CN) and B vanadium compounds with control diet (CB). In 
other tested parameters like TCHOL, TG, and HDL, we did 
not note significant changes.
In turn, V vanadium complex with high-fat diet (AV) 
statistically increased (p  < 0.05) concentration of calcium 
compared to other vanadium complexes as well as high-fat 
diet (AB, ABm, and A). B as well as Bm complexes with high- 
fat diet (AB, ABm) statistically increased (p  < 0.05) level of 
TCHOL compared to high-fat diet (A). Opposite dependence 
for these compounds was observed for activity of PON1. Rats 
fed with high-fat diet in AB and ABm groups had higher level 
of HDL in plasma than AN or AV groups. V as well as B 
complexes with high-fat diet (AV, AB) statistically increased 
(p  < 0.05) the level o fT G  compared to AN and ABm group.
4. Discussion
The role of vanadium in the human body has not been fully 
understoodyet. Thistrace elem entisstillsubjectofnum erous 
biochemical studies to understand its significance to human 
health. Recently, vanadium is considered essential to life. 
Previous studies were primarily related to its antidiabetic 
properties [19, 20]. In animal models of diabetes types 1 and 
2, research was conducted mostly into vanadium complexes 
with organic ligands, for example, bis(maltolato)oxidovana- 
dium(IV), bis(picolinato)oxidovanadium, vanadyl acetylace- 
tone, and vanadyl 3-ethylpentane-2,4-dione (Vet) [21, 22]. 
Organic complexes of vanadium seem to have stronger effects 
and gain an advantage over inorganic salts as potential 
antidiabetic agents. What is more, such complexes have not 
shown adverse effects on gastrointestinal tract. Therefore, in 
this study, we used organic complexes of vanadium(IV) (B 
and Bm complexes) and vanadium(V) (V complex), which 
contain a bipyridine as an organic ligand. In addition, bipyri- 
dine in Bm complex was substituted at position 4 by methyl 
group. The presence of additional group at heterocyclic ring 
of this complex contributed to increasing lipophilicity of it 
which may have importance for enhanced bioavailability. In
our study, we focused on assessing the organic vanadium 
complex on lipid metabolism under conditions of high-fat 
diet in nondiabetes animal model due to the lack of such 
research. This was the main reason for our experiment.
B and Bm complexes with high-fat diet statistically increased 
(p  < 0.05) the level of TCHOL. One of the potential expla- 
nations for the increased value of this parameter would be 
the fact that those compounds also significantly elevated (p  < 
0.05) the level of HDL. However, an important limitation of 
our study was not to determine the level of LDL. In rats fed 
with control diet, we did not note any changes induced by one 
of vanadium complexes. Similarly, Majithiya et al. observed 
that vanadium complex like bis[curcumino]oxidovanadium 
adjusted values of lipid parameters (decreased level of 
TCHOL and TG) in streptozotocin induced diabetic rats, 
without any impact on control nondiabetes rats [23]. Pillaia 
et al. also noted no changes in the level of lipids parameters 
in nondiabetic rats receiving vanadium-3-hydroxy flavone 
complex. In turn, in diabetic rats, the same compound 
showed antidyslipidemic properties [6].
In our study, B and Bm complexes significantly increased 
(p  < 0.05) the level of HDL in combination with a high- 
fat diet. Alike results were obtained among people exposed 
to vanadium compounds [24] as well as rabbits fed with 
a high-cholesterol diet supplemented with vanadium (as 
sodium  metavanadate) [25]. Additionally, Bm complex in 
high-fat diet as the only one of used organic complexes of 
vanadium did not significantly increase the concentration 
of TG. These results encourage us to further research this 
particular compound. Nevertheless, it is possible too that 
hypolipidemic effect of different vanadium complexes is 
strong in the presence of diabetes, contrary to high supply of 
saturated fatty acids, but without carbohydrate disorders.
The consequence of oxidative stress is lowering of PON1 
activity as observed in the course of coronary artery disease 
[26]. Therefore, the attempt to regulate the activity of this 
enzyme may seem particularly significant in treatment of 
this disease. However, in our studies, B and Bm complexes 
of vanadium in conjunction with a high-fat diet caused a 
statistical decrease (p  < 0.05) in the activity of PON1. Further
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V complex administered with control diet affected PON1 in a 
similar way. In turn, Tas et al. noted that vanadyl sulfate with 
standard diet did not influence these parameters in healthy 
rats [26]. The lack of significant difference in PON1 activity 
between A N  and C N  group seems to be quite puzzling. 
Nevertheless, in the studies on the effect of fatty diet on 
PON1, there are discrepancies too; for example, Thomas- 
Moya et al. noted a decrease in the activity of PON1 in 
animals fed with a high-fat as well as hypercholesterolemic 
diets [27]. Kudchodkar et al. observed that diet rich in fish 
oil significantly reduces while trioleate increases the activity 
of it. In turn, in tripalmitate fed rats, no significant change of 
activity of this parameter was observed compared to control 
diet [28]. In a study on people, Calabresi et al. have noted a 
significant increase in the activity of PON1 in patients with 
hyperlipidemia who received u>-3 polyunsaturated fatty acid 
for 8 weeks compared to the placebo group [29]. Therefore, 
the results in these studies indicate how the type of fatty 
acids is an important factor in regulating the activity of 
PON1. What is more, the time of our experiment perhaps 
was too short to observe change in this parameter between 
AN and CN group. Nevertheless, the quite unexpected results 
obtained by Kleemola et al. are also worth noting where 
activity of PON negatively correlated with consumption of 
foods rich in antioxidants [30]. This is another proof of the 
complexity of this issue and the necessity to further research 
to understand the interaction between PON1 activity and 
specific chemical or food component.
5. Conclusions
In the present paper, we have demonstrated that bis(4,4;- 
dimethyl-2,2 -bipyridine)oxidovanadium(IV) sulfate dehy- 
drate (Bm) compound is an interesting object to further study 
as a potential candidate for controlling lipid metabolism in 
condition of high supply of fats, although molecular studies on 
this particular compound are necessary to find out potential 
intracellular mechanisms of diminish side effect of fat diet.
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